What smart money is saying about Humacyte
HUMA
No fund has written a full thesis on Humacyte in our archive, but 1 fund letter reports a position in it, most recently Antipodes Global SMID Active ETF (ASX:MIDS) in September 2026.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in Humacyte on record in the archive was reported in Q3 2026, across 1 fund letter, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- September 2026
“In healthcare the fund exited medical device company Bruker, which was trimmed into strength last quarter, and trimmed biotechnology platform Humacyte whilst adding to Brookdale as mentioned above.”
Humacyte
Read the letters behind these Humacyte positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger